Zynerba Pharmaceuticals, Inc. ZYNE presented positive long-term 38-week data from the phase 2 INSPIRE trial with Zygel in children and adolescents with 22q11.2 deletion syndrome. The data were ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback